Last updated: August 19, 2026
Novo Nordisk sued Mylan Pharmaceuticals in the U.S. District Court for the District of Delaware after Mylan submitted an abbreviated new drug application seeking approval for a generic semaglutide injection. The case concerns generic entry against Novo Nordisk’s Ozempic franchise. Novo asserted patent infringement under 35 U.S.C. § 271(e)(2), triggering the Hatch-Waxman litigation framework and an FDA approval stay. The dispute is strategically important because semaglutide is one of Novo Nordisk’s highest-revenue products and because the asserted patents extend well beyond the basic active-ingredient patent.
What is Novo Nordisk v. Mylan, 1:23-cv-00101?
The case is a Hatch-Waxman patent infringement action filed by Novo Nordisk Inc. against Mylan Pharmaceuticals Inc. in the District of Delaware. The action was filed on January 25, 2023, after Mylan notified Novo Nordisk that it had submitted an ANDA containing a Paragraph IV certification against patents listed for Ozempic.
| Item |
Case information |
| Court |
U.S. District Court for the District of Delaware |
| Civil action |
1:23-cv-00101 |
| Plaintiff |
Novo Nordisk Inc. |
| Defendant |
Mylan Pharmaceuticals Inc. |
| Product at issue |
Generic semaglutide injection |
| Reference product |
Ozempic injection |
| Regulatory pathway |
ANDA under the Hatch-Waxman Act |
| Legal basis |
35 U.S.C. § 271(e)(2) |
| Filing date |
January 25, 2023 |
| Case type |
Abbreviated new drug application patent litigation |
| Primary commercial issue |
Timing of generic semaglutide entry |
Novo’s complaint alleged that Mylan’s ANDA product would infringe patents covering semaglutide, semaglutide formulations, and related pharmaceutical use claims. The litigation was based on Mylan’s Paragraph IV certification, which asserted that the relevant patents were invalid, unenforceable, or would not be infringed by Mylan’s proposed product. [1]
What patents protect Ozempic against Mylan’s ANDA?
Novo Nordisk’s Ozempic patent estate includes compound, formulation, and method-of-use patents. The key patents associated with semaglutide and Ozempic include the following:
| Patent |
General subject matter |
Strategic role |
| U.S. Patent No. 8,129,343 |
Acylated GLP-1 compounds, including semaglutide-related claims |
Core compound protection |
| U.S. Patent No. 10,335,462 |
Semaglutide pharmaceutical compositions and formulations |
Formulation protection |
| U.S. Patent No. 10,617,968 |
Therapeutic use of semaglutide |
Method-of-use protection |
| U.S. Patent No. 11,154,532 |
Semaglutide compound and related pharmaceutical claims |
Later-issued compound protection |
The precise patents asserted against Mylan must be read from the complaint and subsequent infringement contentions. Orange Book listings can change as patents issue, are listed, expire, or are delisted. The FDA Orange Book identifies patent information submitted by the New Drug Application holder, but it does not determine whether a patent is valid or infringed. [2]
How strong is the semaglutide patent estate?
The estate is stronger than a single compound patent because it is layered across several claim categories.
The compound claims address semaglutide itself or closely related chemical structures. Formulation claims target the injectable composition and excipients. Method-of-use claims address treatment of type 2 diabetes and related indications. A generic applicant may avoid one category but still face exposure under another.
The principal weakness for Novo Nordisk is claim overlap. A generic applicant can argue that a formulation patent does not cover its proposed composition, that a method-of-use claim is not infringed because of a narrow label, or that an earlier patent is invalid for lack of written description, enablement, anticipation, or obviousness. Novo’s litigation strategy is to maintain multiple independent infringement theories.
When does Ozempic lose exclusivity?
Ozempic has multiple exclusivity dates because FDA regulatory exclusivity and patent exclusivity are separate rights.
| Protection |
Effect |
| New chemical entity exclusivity |
Prevents ANDA submission for a statutory period after approval |
| Orange Book patents |
Can delay FDA approval or expose an ANDA filer to infringement litigation |
| Pediatric exclusivity |
May add six months to certain listed patent and exclusivity periods |
| Formulation patents |
Can delay or complicate generic approval even after compound protection |
| Method-of-use patents |
May require a label carve-out or create litigation risk |
The principal commercial risk is not necessarily the expiration of the earliest semaglutide patent. It is whether one or more enforceable patents remain available to support a delayed generic launch. Under the Hatch-Waxman Act, a Paragraph IV lawsuit filed within 45 days of receiving notice can impose a 30-month stay of FDA approval, subject to statutory exceptions and court action. [3]
A patent expiration date is not the same as a guaranteed generic launch date. FDA approval, patent settlements, court judgments, manufacturing readiness, and any applicable pediatric exclusivity can materially affect entry timing.
What was Mylan’s Paragraph IV challenge?
Mylan’s ANDA certification challenged Novo Nordisk’s listed patents on the basis that the patents were invalid, unenforceable, or would not be infringed by Mylan’s proposed semaglutide product. The Paragraph IV notice provided the jurisdictional basis for Novo’s suit.
Paragraph IV litigation typically places the following issues before the court:
- Whether Mylan’s proposed semaglutide product falls within the asserted claims.
- Whether the asserted claims are enabled and adequately described.
- Whether the claims are anticipated or obvious.
- Whether Novo Nordisk engaged in inequitable conduct or otherwise rendered a patent unenforceable.
- Whether Mylan’s proposed labeling induces infringement of method-of-use claims.
The ANDA itself is not normally litigated as a commercial product already on the market. The infringement case is based on the statutory act of submitting the ANDA, which creates an artificial act of infringement under Section 271(e)(2). [3]
What defenses are available to Mylan?
Mylan’s defenses likely fall into four groups.
Noninfringement
Mylan can contend that its formulation, concentration, delivery system, or manufacturing process falls outside the asserted patent claims. For method-of-use claims, Mylan may seek a skinny label that omits patented indications or dosing instructions.
Invalidity
The most relevant invalidity theories for semaglutide patents include anticipation, obviousness, lack of written description, lack of enablement, and indefiniteness. Formulation claims may face prior-art challenges based on known GLP-1 formulations, excipient combinations, concentration ranges, and injection-device technology.
Unenforceability
Mylan may allege inequitable conduct if it contends that material information was withheld from the U.S. Patent and Trademark Office with intent to deceive. Such defenses are fact-intensive and generally require clear and convincing proof.
Regulatory and labeling defenses
Mylan may argue that its proposed label does not encourage use covered by Novo’s method-of-use claims. The strength of this defense depends on the FDA-approved label, the scope of the patent claims, and whether the court finds that the remaining label still induces infringement.
What is the Orange Book status of Ozempic?
Ozempic is approved by the FDA as a semaglutide injection for specified type 2 diabetes indications. Novo Nordisk’s listed patents provide the principal basis for Paragraph IV challenges by ANDA applicants. [2, 4]
The Orange Book does not list every form of intellectual property relevant to Ozempic. Patents directed to manufacturing processes, devices, trade secrets, clinical know-how, and unlisted commercial technology may remain important after listed patents expire. Those rights generally do not create the same automatic FDA approval stay as Orange Book-listed patents.
The FDA also does not adjudicate Paragraph IV disputes. Patent validity, infringement, and enforceability are determined by the federal courts.
What litigation status affects Mylan’s generic semaglutide launch?
The case began as a conventional ANDA patent action. Novo’s filing preserved its ability to seek infringement remedies and maintained the statutory FDA approval stay associated with a timely Paragraph IV lawsuit.
No merits judgment establishing Mylan’s right to launch is identified in the cited public case materials. No public settlement terms are identified in those materials. The commercial status therefore depends on later docket activity, any confidential or public settlement, court rulings on claim construction and summary judgment, and the ultimate FDA approval path.
Possible case outcomes include:
| Outcome |
Commercial consequence |
| Novo wins on all blocking claims |
Mylan’s approval or launch is delayed until patent expiration or settlement |
| Mylan wins on all blocking claims |
Earlier launch becomes possible, subject to FDA approval |
| Mixed judgment |
Mylan may launch only after modifying formulation, label, or manufacturing process |
| Settlement |
Entry date depends on the negotiated license and patent rights |
| Dismissal without public terms |
Does not by itself establish patent invalidity or noninfringement |
Does the case involve biosimilar risk?
No. Mylan’s product is a generic drug application, not a biosimilar application.
Semaglutide is a chemically defined peptide drug. The relevant regulatory pathway is an ANDA under Section 505(j), assuming the proposed product can satisfy the applicable sameness, equivalence, and other FDA requirements. A biosimilar application under Section 351(k) applies to biological products and follows a different approval and patent-information framework. [3, 5]
The commercial risk is therefore generic competition rather than biosimilar substitution.
What generic entry risks exist for Ozempic?
The main entry scenarios are:
At-risk launch
Mylan could launch before final resolution of all patent disputes after obtaining FDA approval. That would expose Mylan to potential damages, an injunction, and accelerated litigation over any remaining claims.
Court-authorized launch
A judgment of noninfringement or invalidity could remove the principal patent barrier. Mylan would still need final FDA approval and a commercially viable supply chain.
Settlement-based entry
Novo Nordisk could grant Mylan a license beginning on an agreed date. Such settlements often include a launch date, a royalty, restrictions on authorized or independent generic supply, and provisions addressing later-issued patents.
Delayed entry after patent expiry
Mylan may remain blocked until the last enforceable patent covering its proposed product expires, unless it changes the product or label.
How does this case compare with Ozempic’s broader competitive landscape?
Novo Nordisk faces multiple forms of competition:
| Competitor type |
Example |
Risk to Novo |
| ANDA applicants |
Mylan and other generic manufacturers |
Price erosion after approval and launch |
| Branded GLP-1 drugs |
Eli Lilly’s Mounjaro and Zepbound |
Share loss before generic entry |
| Compounded products |
Compounded semaglutide during shortage conditions |
Pricing and access pressure |
| Oral GLP-1 products |
Rybelsus and emerging oral competitors |
Formulation and indication substitution |
| Other diabetes therapies |
SGLT2 inhibitors and insulin products |
Prescriber and payer substitution |
Ozempic’s patent estate has greater commercial value than a conventional single-product patent portfolio because semaglutide supports multiple branded products, including Ozempic, Wegovy, and Rybelsus. The products have different indications, dosage forms, and patent listings. A ruling in the Mylan case may affect one product configuration without resolving every patent issue across the semaglutide franchise.
What is the revenue exposure from Mylan’s challenge?
Ozempic is a major Novo Nordisk revenue driver. Novo Nordisk reported 2023 sales of DKK 95.7 billion for Ozempic, while the broader semaglutide portfolio generated substantially higher sales when Wegovy and Rybelsus were included. [6]
A successful generic launch would likely create:
- Immediate price pressure in the U.S. market.
- Reduced pharmacy and payer reimbursement.
- Increased substitution among patients using semaglutide for diabetes.
- Potential spillover effects on Novo Nordisk’s broader injectable GLP-1 portfolio.
- Greater pressure on manufacturing scale, supply allocation, and contracting strategy.
The magnitude depends on launch timing, the number of approved ANDA applicants, the availability of authorized generics, payer coverage, and whether Mylan launches with a full or carved-out label.
Key Takeaways
- Novo Nordisk v. Mylan, 1:23-cv-00101, is a Hatch-Waxman case concerning Mylan’s proposed generic semaglutide injection.
- The reference product is Ozempic.
- Novo relies on a layered patent estate covering semaglutide, formulations, and therapeutic uses.
- Mylan’s Paragraph IV challenge creates the statutory basis for litigation and an FDA approval stay.
- The case does not involve biosimilar substitution.
- A patent expiration date alone does not establish the earliest commercial generic launch date.
- The principal business risk is U.S. price erosion across Novo Nordisk’s semaglutide franchise.
- Publicly identified materials do not establish a merits judgment or settlement granting Mylan a launch date.
FAQs
Is Mylan’s proposed product a generic Ozempic?
Yes. Mylan’s application is an ANDA seeking approval for a generic semaglutide injection referencing Ozempic.
Can Mylan launch before all Ozempic patents expire?
Only if it obtains a judgment clearing the relevant patents, reaches a license or settlement with Novo Nordisk, changes its product or label to avoid infringement, or accepts the risk of an at-risk launch.
Are Ozempic patents the same as Wegovy patents?
Some semaglutide patents may overlap across products, but patent listings and method-of-use claims can differ by indication, dosage, formulation, and FDA-approved labeling.
Does a Paragraph IV certification mean Mylan will launch?
No. It means Mylan has challenged listed patents. FDA approval, patent litigation, settlement terms, and manufacturing readiness remain separate issues.
Could Mylan’s case affect Rybelsus?
Potentially, but the effect depends on the patents asserted, the product formulation, and the specific claims at issue. Injectable Ozempic litigation does not automatically resolve patent protection for oral Rybelsus.
References
-
Novo Nordisk Inc. v. Mylan Pharmaceuticals Inc., No. 1:23-cv-00101, Complaint, U.S. District Court for the District of Delaware (Jan. 25, 2023).
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: The Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
U.S. Code. (2024). 21 U.S.C. § 355; 35 U.S.C. §§ 271(e)(2), 271(e)(4).
-
U.S. Food and Drug Administration. (2024). Ozempic prescribing information. Novo Nordisk.
-
U.S. Food and Drug Administration. (2024). Biosimilar and interchangeable biosimilar products. https://www.fda.gov/drugs/therapeutic-biologics-applications-bla/biosimilar-product-information
-
Novo Nordisk A/S. (2024). Annual report 2023. https://www.novonordisk.com/investors/annual-report.html
